Streetbeat News

Analyst Ratings

VVI

Oppenheimer analyst Tyler Batory maintains an Outperform rating on Viad (NYSE:VVI) and raises the price target from $34 to $36.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 3:53 pm

ILLM

Needham analyst Laura Martin has reiterated a 'Buy' rating on Illumin Holdings (NASDAQ:ILLM) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 3:52 pm

NABL

Needham analyst Mike Cikos maintains a Buy rating on N-able (NYSE:NABL) and raises the price target from $15.5 to $16.5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 3:52 pm

NOMD

Citigroup analyst Wendy Nicholson has maintained a 'Buy' rating on Nomad Foods (NYSE:NOMD), but lowered the price target from $25 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 3:52 pm

BLNK

Blink Charging's Chief Revenue Officer, Mike Battaglia, at Benzinga's EV Conference, commented on the company's FY guidance raise, stating that there is hardly any other industry growing as fast as EV charging.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 3:52 pm

TH

Oppenheimer analyst Scott Schneeberger has maintained an 'Outperform' rating on Target Hospitality (NASDAQ:TH), but lowered the price target from $20 to $17.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 3:51 pm

PCT

Oppenheimer analyst Noah Kaye maintains an Outperform rating on PureCycle Technologies (NASDAQ:PCT) and raises the price target from $14 to $18.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 3:51 pm

PLRX

Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) and raised the price target from $51 to $52.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 3:50 pm

C

PTVE

Citigroup analyst Anthony Pettinari has maintained a Neutral rating on Pactiv Evergreen (NASDAQ:PTVE) and raised the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 3:50 pm

LUMO

Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Lumos Pharma (NASDAQ:LUMO), but lowered the price target from $18 to $17.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 3:49 pm